Inside Biotech: Biogen’s Alzheimer’s setback still points to a bigger shift in the field

Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR

Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled

Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer

Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger

Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger

Biogen buys Apellis (APLS) for $41 cash plus CVR per share

Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share

Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR

Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout

Biogen deal: Apellis (APLS) director’s shares and options cashed out

Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured

Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR

Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger

Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap

Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders

Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout